8-K current report · filed Nov 18, 2026

Voyager Therapeutics, Inc. (VYGR) 8-K Current Report: November 18, 2026

Item 2.02Item EX-99.1VYGR overview

Short answer

Voyager Therapeutics, Inc. (VYGR) filed an 8-K current report with the SEC on November 18, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results and corporate updates announced on November 5, 2026.

Voyager Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results and corporate updates announced on November 5, 2026
  • Full results and management commentary available in Exhibit 99.1, the accompanying press release

Item EX-99.1 · Exhibit EX-99.1

  • Q3 collaboration revenue $4.0M, down from $13.4M, reflecting reduced Neurocrine revenue as programs move beyond research
  • R&D expense $24.4M, down from $35.9M, while net loss narrowed to $24.7M from $27.9M
  • Cash, equivalents and marketable securities $132.1M at September 30, supporting planned operations into Q2 2028
  • VY7523 tau-PET efficacy data remains expected in Q4 2026, a major near-term Alzheimer’s valuation catalyst
  • VY1706 dosing expected within months, with initial safety data targeted for Q1 2027 and Neurocrine’s NBIB-223 entering Phase 1 soon

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Voyager Therapeutics, Inc. 8-K filings

Get the next VYGR 8-K as it lands

Follow VYGR for push alerts, or ask the research agent what this filing means.